A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.

Dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent

Capodanno, Davide;
2019-01-01

Abstract

A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence.
File in questo prodotto:
File Dimensione Formato  
dual-antiplatelet-therapy-strategies-and-clinical-outcomes-for-a-polymer-free-bi.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.05 MB
Formato Adobe PDF
1.05 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/367477
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact